ABSTRACT
Guizhi decoction come from Typhoid Theory written by Zhang Zhongjing, a famous physician in the Han dynasty. It is called "the leading group of the group" by later doctors. At present, Guizhi decoction is widely used in treatment of many diseases of internal, external, gynecologic and other diseases. This article discusses the clinical application and mechanism of Guizhi decoction in two aspects. This article expounds that Guizhi decoction is widely used in colds, febrile diseases, various perspiration, digestive system diseases and respiratory diseases, Some diseases, such as ear, nose and throat disease, nervous system disease, cardiac autonomic neuropathy, and bone and joint disease. The mechanism of Guizhi decoction in the treatment of diseases may be related to the mechanism of biaxial regulation of body temperature and gastrointestinal motility, mucosal immune intervention, secretion of sweat glands, inflammation immune function and myocardial protective effect and so on.
ABSTRACT
<p><b>OBJECTIVE</b>To investigate and analyze the therapeutic level and the existing problems on acute myocardial infarction (AMI) management in Beijing.</p><p><b>METHODS</b>We collected clinic data of 1242 AMI patients from 12 hospitals in Beijing, from January 2000 to March 2001, using a uniformed questionnaire, and evaluated the status of the diagnosis and treatment of AMI according to the Chinese guidelines issued on Decmeber 2001. Corresponding factors which influencing the mortality were also analyzed by one-way factor and multiple factors analysis methodologies.</p><p><b>RESULTS</b>The mean age of the 1242 AMI patients was 63.0 years old and about one third of them were under 55 years old. In hospitals, the total mortality was 9.10%. 37.9% of the patients had received therapy of the intravenous thrombolysis and emergency PCI with a total rate of reperfusion therapy as 56.0%. The in-hospital rates of drug use were as follows: Nitrates 90.0%, Aspirin 87.8%, heparin 88.7%, beta-blockers 73.4%, angiotensin converting enzyme inhibitors(ACEI) 77.6%, lipid regulating agents 43.6%. The rate of intravenous therapy of TCM by promoting the blood circulation and supplementing the vital energy was 30.5%. Results from multiple factors analysis showed that the compositive factors which could lower the mortality were reperfusion therapy,lipid regulating agents, intravenous therapy of TCM, beta-blockers, ACEI, lower molecule heparin and digitalis.</p><p><b>CONCLUSION</b>Data from this study showed that there still existed a gap between clinical management on AMI and the guideline in Beijing. To set up a straightway passage of reperfusion therapy, to become more standardized to follow the guideline in undertaking the medical treatment practice, and to go deep into discuss the status of TCM on AMI management seemed the important tasks we are facing.</p>
Subject(s)
Female , Humans , Male , Middle Aged , China , Cities , Guideline Adherence , Myocardial Infarction , Therapeutics , Quality of Health CareABSTRACT
<p><b>OBJECTIVE</b>To analyze the current status of clinical studies of TCM in preventing and treating angina pectoris of coronary heart disease.</p><p><b>METHODS</b>A statistical analysis of articles regarding the use of TCM in preventing and treating angina pectoris, published in TCM core journals or journals of TCM university (college) from January 2001 to June 2002 was conducted, the items analyzed included the differentiation of stable angina (SA) and unstable angina (UA), the grading or stratifying, standard for therapeutic efficacy evaluation, standardized drug therapy of UA (according to the "Suggestion on the diagnosis and treatment of UA" formulated by Society of Cardiovascular Disease, Chinese Medical Association, etc.</p><p><b>RESULTS</b>From the 44 articles that retrieved, UA and SA was not differed in 29 articles (65.9%), among which 11 articles came from provincial, national TCM institute or hospital affiliated to TCM university (college). In the 34 articles dealing with UA, only 3 articles mentioned the standardized drug therapy. Standard of therapeutic efficacy evaluation announced in 1979 was used in 35 articles (79.5%).</p><p><b>CONCLUSION</b>Most articles dealing with clinical study on TCM prevention and treatment of angina pectoris, UA and SA, have the flaws of un-standardized, lacking in compact and insufficient science. Improvement of related standard for clinical therapeutic efficacy evaluation needs to be further perfected.</p>